Novel Strategies and Treatments in Chronic Lymphocytic Leukemia
John Allan, MD, speaks to the exciting future of treatments for chronic lymphocytic leukemia.
Video Player is loading.
Case: A 70-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia
Initial Presentation:
- A 70-year-old woman presented to her PCP for a routine checkup complaining of moderate, progressive fatigue and unintended weight loss over the last 4 months.
- PMH: hypercholesterolemia (well controlled on medication; reports having a relatively healthy diet)
- SH: Retired nurse; exercises at least 30 minutes per day most days of the week; enjoys spending time with her grandkids and traveling with her spouse; ~1-2 drinks in social settings per week
- PE: vital signs WNL, right cervical lymphadenopathy~2.7 cm, spleen palpable 5 cm below costal margin, otherwise well-appearing
- Laboratory findings:
- WBC 186,000; 75% lymphocytes
- Hb 9.4 g/dL
- Platelets 85 X 109/L
- Cr Cl: 61 ml/min
- Flow cytometry; CD5+, CD19+, CD23+
- beta2M, 3.8 mg/L
- IGHV mutational status: unmutated; TP53 unmutated
- ECOG PS 0
- BM biopsy; diffuse infiltration by CLL
Treatment:
- Options for treatment were reviewed and discussed with the patient, her spouse, and the care team.
- The decision was made to initiate the patient on fixed duration venetoclax + obinutuzumab.
Recent Videos
How would therapeutic options change if this patient was asymptomatic?
Lenvatinib and Depth of Response in Advanced uHCC: Insights From REFLECT
Clinical Insights and Patient Considerations for Frontline TKI Therapy in Advanced uHCC
Sequencing Multiple Lines of Therapy in Metastatic RCC
Individualized Approaches in 3L Treatment Selection for mRCC
Role of Systemic Therapy in TACE-Eligible Patients
Managing Disease Progression After TACE
Exploring Fixed-Duration Ibrutinib and Venetoclax in CLL Treatment
Understanding BPDCN: From Disease Presentation to Diagnosis
A 62-Year-Old Man Who Is Newly Diagnosed With BPDCN
Related Content
Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison
February 4th 2025Article
During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.
Read More
